# Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas

> **NCT02822066** · PHASE1,PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 60 (estimated)

## Conditions studied

- Refractory Neoplasms

## Interventions

- **PROCEDURE:** Electroporation

## Key facts

- **NCT ID:** NCT02822066
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02822066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02822066, "Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02822066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*